Hedgehog Pathway Inhibition.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26919418.
- Also identified by DOI 10.1016/j.cell.2016.02.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).
Medical subject headings
- Anilides
- Antineoplastic Agents
- Biphenyl Compounds
- Basal Cell Carcinoma
- Hedgehog Proteins
- Pyridines
- Signal Transduction
- Skin Neoplasms